William Abraham, M.D., FACC, discusses advances in heart failure device treatment technologies at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 annual meeting. He is director of the division of cardiovascular medicine and a professor of internal medicine, physiology and cell biology at The Ohio State University Wexner Medical Center. He also served as principal investigator of the CHAMPION Trial for the CardioMEMS device. Read the article "Reducing Heart Failure Readmissions."
VIDEO: Transcatheter Mitral Valve Interventions at Henry Ford Hospital
Marvin Eng, M.D., structural fellowship director at Henry Ford Health System, and William O'Neill, M.D., director of the Henry Ford Hospital structural heart program, explain the mitral valve repair program at Henry Ford.
The hospital performs a large number of transcatheter mitral valve repairs, including MitraClip and with its involvement in trials for investigational device technologies.
A discussion with Michael Reardon, M.D. about the state of transcatheter aortic valve replacement (TAVR) as of late 2016. He is a professor of cardiothoracic surgery at Houston Methodist DeBakey Heart and Vascular Center, was the chairman of the patient screening committee for the CoreValve U.S. pivotal trial, nation PI on the Lotus Pivotal Trial, and the national PI of the ongoing the CoreValve intermediate and low-risk trials. Read more in the article "Trends in Transcatheter Aortic Valve Replacement (TAVR)."
Brijeshwar Maini, M.D., and Brian Bethea, M.D., from Tenet Florida’s structural heart program, explain the importance of building a good heart team and how that team should interact. They gave a presentation on image guidance for structural heart procedures at TCT 2016, but focused repeatedly on the need for close collaboration to be successful. Read more in the article "Requirements for Interventional Echocardiographers."
Juan Granada, M.D., executive director and chief scientific officer of the Cardiovascular Research Foundation's Skirball Center for Innovation, explains the shortcomings of the first bioresorbable stent on the U.S. market, proper patient selection and what new BRS technologies are in development. Granada presented numerous sessions on bioresorbable scaffolds at TCT 2016. Read more about bioresorbable stents in "Tempering the Bioresorbable Stent Euphoria Following FDA Clearance of the Absorb."
Krishna Rocha-Singh, M.D., Prairie Vascular Institute, Springfield, Ill., explains advancements in device therapy for hypertension at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 annual meeting. He was involved in the SYMPLICITY HTN-3 denervation trial and is the principal investigator for the ongoing Rox Coupler arteriovenous device trial. Watch the VIDEO “New Approaches to Denervation Therapy.”
David Kandzari, M.D., director of interventional cardiology and chief scientific officer, Piedmont Heart Institute, Atlanta, Ga., explains the impact of the EXCEL Trial at TCT 2016. Piedmont recruited the highest number of patients for the large, randomized trial found the Xience V drug-eluting stent had comparable outcomes to coronary artery bypass graft surgery. This is the first time this parity has been shown in a large trial. Read the article "Stents, Bypass Surgery Equally Safe and Effective for Many With Left Main Heart Disease."
Studies have shown transcatheter aortic valve replacement (TAVR) has an increased risk of stroke and cerebral damage due to emboli released during the procedure. Recent clinical data show the extent of this damage on MRI. Several TAVR embolic protection systems are being developed to reduce this damage. This video explains one of those systems. Read about trial data presented at TCT 2016 "Delirium Significantly Associated With Brain Lesions in Patients Post-TAVR." Read the article, “TAVR Embolic Protection Did Not Reduce Emboli Brain Lesions,” which was a second trial presented at TCT 2016.
This video, provided by Zoll, demonstrates how cardiologists can explain sudden cardiac death to patients. It is critical to educate patients who are at risk of sudden cardiac arrest (SCA), so Rahul Doshi, M.D., director of electrophysiology, associate professor of clinical medicine, Keck Medical Center of University of Southern California, explains sudden cardiac death (SCD) to his patients using a simple illustration. Visit SCDFacts.org for additional resources for you and your team to support the SCD conversation with your patients. One in five post-AMI patients have been shown to be at high risk of dying after PCI.1 The majority of mortality in AMI patients post-PCI occurs in the first three months — one out of every 10 high-risk patients die, with about 60 percent of this mortality due to SCD.[1,2]
With quality of care and cost efficiency at the top of your mind, there is no room in your hospital for waste from high-value supplies. However, managing your critical supplies in the cath lab can be a challenge. How can you get the supply waste in your facility under control? Watch this short video to learn how an automated inventory management solution could help you reduce the waste in your hospital while improving your total cost of care. For more information visit www.cardinalhealth.com.
With bundled payments putting increased pressure on hospitals to manage supply costs while providing quality patient care, there is no room in your cath lab for high-value medical device waste. An automated inventory management solution could help you find and reduce the waste hiding in your supply chain while helping to improve your total cost of care. Visit cardinalhealth.com/CIMS.
This video, provided by Shockwave Medical, demonstrates the Lithoplasty System. It uses ultrasonic waves to treatment calcified plaque in patients with peripheral artery disease (PAD). It was cleared by the U.S. FDA in September 2016. The technology is the first of its kind in interventional cardiovascular medicine. Using similar lithotripsy technology that is already in use to break up kidney stones, the balloon catheter cracks and breaks up calcium in vessel walls, without the need to over inflate the balloon, which can lead to extensive vessel damage. Read the article "FDA Clears Lithoplasty Balloon That Shatters Calcified Lesions With Ultrasound."
Pacemakers, stents and bandages — keeping tracking of what is on hand and accurately capturing charges can be a challenge. What if you could track, manage and analyze your cath lab inventory – low cost to high value – to reveal powerful business intelligence and shine a light on new savings and revenue capture?
You have bigger priorities than managing inventory. Patient safety, quality care and clinician satisfaction top the list. But automated technology can help you improve the way you purchase, control and manage your cath lab inventory, allowing you to positively support your top priorities – and your hospital’s overall performance. For more information, watch this archived webinar on inventory management in the cath lab
Interview with Stephen Little, M.D., medical director of the Valve Clinic at the Houston Methodist DeBakey Heart and Vascular Center, at the American Society of Echocardiography (ASE) 2016 annual meeting. He explains the technologies his center is using to aid transcatheter structural heart procedure navigation, including TAVR, transcatheter mitral valve replacement (TMVR), LAA occlusion, and septal defect occlusions. Read the article “Requirements for Interventional Echocardiographers.” Also, watch the VIDEO "What is Required for Interventional Echo - Discussion With Rebecca Hahn."
Interview with Rebecca Hahn, M.D., FASE, Columbia University Medical Center, New York, at the American Society of Echocardiography (ASE) 2016 meeting. She is an expert in the new subspecialty of interventional echo and discussed considerations for hospitals thinking of creating interventional echo programs to help guide complex transcatheter structural heart procedures in the cath lab or hybrid OR. Read the article “Requirements for Interventional Echocardiographers.” Also, watch the related VIDEO "Transcatheter Structural Heart Procedure Navigation Technology Advances."
This is an animation, supplied by Gore, demonstrated how the Cardioform Septal Occluder is implanted for the transcatheter closure of ASDs or PFOs. It is a permanent implant consisting of a wire frame covered with a thin ePTFE membrane. The wire frame is made of a nitinol alloy. Read more about closing holes in the heart.
DAIC Editor Dave Fornell takes a tour of some of the trends and interesting new technologies from the vendor booths on the expo floor at the 2016 meeting of the American College of Cardiology (ACC).
David Holmes, M.D., professor of medicine, Mayo Clinic College of Medicine and consultant, Department of Internal Medicine, Division of Cardiovascular Diseases, shares details from his presentations at ACC.16 regarding the Watchman left atrial appendage occluder.
MDbuyline clinical analyst Tom Watson, BS, RCVT, explains the new hemodynamic system technology trends at ACC.16. All technologies are being increasingly integrated into the electronic medical record. Read the article “Improving Cath Lab Efficiency With Today’s Hemodynamic Systems.”
John Carroll, M.D., professor of medicine at the University of Colorado School of Medicine, and director of interventional cardiology at the University of Colorado Hospital, explains his late-breaker presentation data at ACC.16. He researched outcomes and procedural volume based on the transcatheter aortic valve replacement (TAVR) STS/ACC TVT Registry.
Chandan Devireddy, M.D., assistant professor of medicine at Emory Healthcare in Atlanta and an investigator in the PARTNER trials, discusses the positive late-breaking PARTNER II and IIA data presented at ACC.16. Among the key measures in these trials was the stroke rate, which is now the same as surgery.
A discussion on the adoption rate of FFR-CT with Dr. Campbell Rogers, chief medical officer of HeartFlow. It is the first vendor to gain FDA approval for noninvasive, virtual fractional flow reserve measurements derived from cardiac computed tomography scans. Read the article "Clinical Applications of FFR-CT."
Gregg Stone, M.D., director of cardiovascular research and education at Columbia University Medical Center / New York-Presbyterian Hospital, explains ABSORB Trial data showing bioresorbable stents had poor outcomes in small coronary vessels. This might be included as a restriction in the instructions for use of the Abbott Absorb stent, which is currently pending FDA final review. Read the related article "Questions Remain on Future of Bioresorbable Stents." Also, read the article "FDA Approves First Totally Bioresorbable Stent."
Dr. Vinod Thourani, professor of surgery, Division of Cardiothoracic Surgery, Department of Surgery, Emory University School of Medicine and a co-investigator for the PARTNER II Trial, discusses the biggest news item from ACC.16 — the Sapien 3 TAVR device performed better that surgical aortic valve replacement.
Managing inventory in the procedural area is often a challenge that creates substantial waste and inefficiency that impacts your bottom line. Understanding how to overcome the top barriers allows you to spend more time on patient care and less time on tackling your supplies. Learn how you can manage inventory more effectively with Cardinal Health Inventory Management Solutions. For more information visit cardinalhealth.com/cims.
ITN/DAIC Editor Dave Fornell shows his choices for some of the most innovative new imaging technologies on the expo floor at Radiological Society of North America (RSNA) 2015 meeting.
DAIC Editor Dave Fornell offers his choices for the most innovative new interventional cardiovascular technologies presented on the expo floor and in sessions at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) meeting.
Tom Watson, clinical analyst for MDBuyLine, and DAIC Dave Fornell discuss some of the technology trends at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting.
Robert Schwartz, M.D., medical director at the Minnesota Heart Institute, explains new applications for denervation therapies for hypertension, heart failure and other disease.
Guillaume Baillaird, CEO of ControlRad Systems, described how his company's technology can significantly reduce radiation dose to staff and patients during angiography procedures.
Sunil Rao, M.D., associate professor of medicine and a member in the Duke University Clinical Research Institute, a leading proponent of radial access offers insights as to where radial access is at in the United States. Radial access is rapidly growing and was a topic of late-breaking trials presented at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting. Read the article "Radial Access Adoption in the United States."
Ziad Ali, M.D., associate director of translational medicine, Columbia University Medical Center / New York-Presbyterian Hospital, explains recent advances in IVUS, OCT and FFR. This was a big topics discussed at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting. Read the article “10 Reasons Why You Need Supplemental Imaging in the Cath Lab.”
Dr. Stephen Worthley, Ph.D., director of the cardiac cath labs at Royal Adelaide Hospital at the University of Adelaide in Australia, and co-principal investigator of Medtronic's recently launched international drug-filled stent (DFS) clinical trial, explains DFS the new technology. This was among the top innovations presented at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting.
Todd Brinton, M.D., clinical associate professor and consulting associate professor of bioengineering at Stanford University Medical Center, explains balloon-based lithoplasty as a new alternative for treating heavily calcified coronary and peripheral vascular disease lesions. The technology was among the new innovations at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting.
Manesh Patel, M.D., associate professor of medicine, and director of interventional cardiology and the cath labs at Duke University, explains the innovations in interventional heart failure technologies, including the Aortix percutaneous heart pump. This was among the innovations presented at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting. Read more on this device.
Dean Kereiakes, M.D., medical director of The Christ Hospital Heart and Vascular Center, and a lead investigator for both the ABSORB and SYNERGY stent trials, discussed the latest developments in bioresorbable stent technology. Bioresorbable stent technology was among the top innovations presented at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting. Read the article "FDA Approves First Totally Bioresorbable Stent."
DAIC Editor Dave Fornell shares some of the most innovative new technologies shown on the expo floor and discusses in sessions at the Society of Cardiovascular Computed Tomography (SCCT) 2015 annual meeting.
Interview with James Min, M.D., Professor of Radiology and Medicine and Director of Dalio Institute of Cardiovascular Medicine, Weill Cornell, New York Presbyterian Hospital. Watch the VIDEO “Early U.S. Experience With FFR-CT in Evaluating ED Chest Pain Presentation.” A discussion with Simon Dixon, M.D., MBChB, on the use of fractional flow reserve-computed tomography (FFR-CT) to evaluate chest pain patients in the emergency departmenat Beaumont Hospital in Royal Oak, Mich. Read the article "What is New in FFR Technology."
Interview at the American Society of Echocardiography (ASE) annual meeting with Federico Asch, M.D., M.D., FACC, FASE, associate director of the echocardiography core lab at Medstar Health Research Institute and assistant professor of medicine (cardiology) at Georgetown University. He explains how ultrasound might have a roll in the future for breaking up clots and targeted delivery of gene and drug therapies.
Interview with Steve Goldstein, M.D., director, noninvasive lab, Medstar Washington Heart Institute, Washington, D.C., on the uses of echo guidance for interventional procedures in the cath lab.